linkedin post 2013-06-22 06:02:50
DRUG RESISTANCE in cancer is due to rapid mutations and tumor heterogeneity allowing resistant mutations to grow up a new cell ID. Biopsies to track these genetic changes are impractical. Researchers are making headway to use blood borne tumor DNA to monitor and track the mutations marking drug resistance. This is an important area if oncology research. http://lnkd.in/jvD-EU View in LinkedIn